Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMT Genotype and Cannabinoid Effects on Psychosis Model
NCT02492074Phase 1Withdrawn
- Sponsor
- Central Institute of Mental Health
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol and dronabinol in psychosis (4 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Positive and Negative Syndrome Scale Total Score up to 6 hours. Planned start Dec 2024; status: withdrawn.
02
Drugs
cannabidioldronabinol
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT02492074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492074.